SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the impact of Elon Musk's recent $1 billion stock purchase, with some seeing it as a positive signal and others questioning its long-term effect. Discussions include potential catalysts like robotaxis and AI advancements, as well as concerns about valuation and competition. Bearish sentiment is also present, with some traders anticipating a pullback.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

$BBAI is trending amid community excitement surrounding AI-driven security solutions, particularly after news of its technology accelerating passenger processing at Nashville International Airport. Traders are speculating about a potential short squeeze and new contracts, drawing comparisons to Palantir while emphasizing the company's growing presence in the AI sector. The community is closely monitoring the stock's chart setup and breakout potential.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending following news of a private placement to support acquisitions in the defense sector, sparking discussions about the company's shift towards aerospace and defense. Community members are debating the potential for a short squeeze and speculating on future news, including possible acquisitions and contract announcements. Despite some concerns about dilution and past volatility, optimism remains due to insider ownership and potential benefits from increasing defense spending.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The crypto, WAGMI.X, is trending as users highlight its strong community, branding, and the broad appeal of its "We're All Gonna Make It" (WAGMI) message within the crypto and stock investing space. Many community members are excited about WAGMI's potential, viewing it as more than just a meme, but a movement on the Solana blockchain. Discussions also focus on its long-term potential and the active efforts of its community.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending as investors discuss the recent authorization of an additional $500 million for share repurchases, signaling management's confidence. The community is debating whether the buyback is enough to ignite an uptrend, especially amid broader concerns about consumer spending and the stock's recent performance. Some are also discussing the valuation in light of expansion plans and competition in the restaurant sector.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending due to news of its Teal Drones Black Widow System being approved for the NATO Support and Procurement Agency catalogue, potentially opening doors to significant international contracts. The drone's inclusion in the NATO catalogue has sparked discussions about revenue potential, future contracts, and comparisons to competitors, with many expressing bullish sentiment. Community members are actively discussing potential impact of the NATO approval.

Pitbull

Pitbull ($PIT.X) is trending due to increased visibility on Dextools and strong community engagement, with the #PitbullToken community actively highlighting its decentralized nature and recent volume surge on LBank. Community members are emphasizing the token's unique structure with no team wallets and a large portion of the supply burned, promoting it as a project fully in the hands of its holders. The broader conversation revolves around the project's commitment to building and decentralization within the BNB Chain.

Where delusion meets decentralization     What is a Qoomer?  Qoomer is not just a guy. He’s the bagholder who believed. He’s the degen who leveraged his rent. He’s the chainmaxi who fell in love with his portfolio. He’s down 98% and still tweeting "WAGMI". He didn’t buy the top. the market betrayed him. Qoomer is the final form of hopium addiction. Qoomer token? Yes. $QOOMER 1 Billion  Community We’re not early. We’re delusional. We won’t make it. but at least we’re not normies.  Join the echo chamber on telegram and post your -90% screenshots. Roadmap  Q1: cope Q2: double down Q3: mint regret Q4: spiritual awakening or tax fraud  Disclaimer Qoomer is not financial advice. Nothing here is. This website is a mirror. if you feel seen, you might already be one of us.

Qoomer

Qoomer is trending as social media buzz points to strong community enthusiasm and heavy buying. Investors are expressing bullish sentiment, drawing comparisons to other meme coins and anticipating significant upward movement. The community emphasizes that early investment could yield substantial returns.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's Entertainment is trending due to disappointing earnings, including missed revenue and profit targets, sparking concerns about its financial health. The community is actively discussing potential downside risks, with some anticipating a further decline in the stock price. Investors are also weighing the impact of a new CEO and broader economic factors on the company's future performance.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential breakout past a key resistance level, fueled by recent institutional inflows and positive on-chain data. Some analysts are setting ambitious price targets, while others are closely watching for a healthy pullback before further gains. Community members are also actively promoting new Solana-based meme coins, indicating a growing interest in the Solana ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Shares of Ocular Therapeutix (OCUL) plunged nearly 17% on Monday, marking their steepest single-day decline since April, as the biotech firm's fourth-quarter earnings missed expectations. The stock extended losses in after-hours trading.The company posted Q4 revenue of $17.08 million, slightly below analysts' estimates of $17.16 million. While its quarterly loss narrowed to $0.29 per share from $0.35 a year earlier, it still came in wider than the Street's forecast of $0.27 per share.Ocular also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet age-related macular degeneration (wet AMD), shifting the timeline from Q4 2025 to Q1 2026. The adjustment follows FDA approval of study protocol changes under a Special Protocol Agreement (SPA).Despite the earnings disappointment and trial delay, Ocular reaffirmed its financial stability, reporting a cash balance of $392.1 million as of Dec. 31, 2024, which it expects to fund operations into 2028 without the need for additional capital raises this year.Retail sentiment on Stocktwits flipped to 'bullish' from 'bearish' amid the sell-off, with message volume surging 2,200% by the end of Monday's regular session.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCUL_sentiment_and_message_meter_as_of_March_3_4b0b51c1ff.png" alt="OCUL sentiment and message meter as of March 3.png" width="1316" height="316"><figcaption>OCUL sentiment and message meter as of March 3 | source: Stocktwits</figcaption></figure>One trader argued that selling the stock now could mean missing a long-term payoff, setting a personal price target of $25 — implying a potential 500% upside from the last close.&nbsp;<stembedurl>https://stocktwits.com/WaterskiUP/message/606602356</stembedurl>Another investor expressed optimism but questioned why the company didn't provide updated enrollment figures for its SOL-R (Phase 3, wet AMD) trial or 2025 revenue guidance for Dextenza, an FDA-approved corticosteroid for post-surgical inflammation and allergic conjunctivitis.<stembedurl>https://stocktwits.com/esu89/message/606599224</stembedurl>Ocular modified its SOL-R trial protocol, reducing the number of randomized subjects from 825 to 555, citing "strong" ongoing enrollment. As of Jan. 10, 2025, 311 subjects had been enrolled across various stages in the U.S. and South America.<a href="https://stocktwits.com/symbol/OCUL">OCUL stock</a> has tumbled more than 31% year-to-date.&nbsp;Wall Street analysts remain bullish — of the nine analysts covering the stock, five rate it a 'Buy,' while four call it a 'Strong Buy,' according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling.

Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback

The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.

Equity

Optimistic Buy Rating for Ocular Therapeutix Amid Promising Axpaxli Trials and Strategic Execution

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix (OCUL Research Report), with a pr...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix (OCUL Research Report) today and set a price target of $15.00. The...

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

 After hitting the beach during yesterday's blistering Juneteenth holiday, the "buy...

Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)

Latest Ratings for OCUL
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021JMP SecuritiesMaintainsMarket Outperform Oct 2021HC Wainwright & Co.MaintainsBuy
 View More...

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

OCUL
Ocular Therapeutix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OCUL News

OCUL Ocular Therapeutix Inc